OSTEONECROSIS and Oxycontin

PatientsVille

OSTEONECROSIS Symptoms and Causes

Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In Osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down.

You can have Osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties.

At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well.

No one is sure what causes the disease. Risk factors include

Long-term steroid treatment
Alcohol abuse
Joint injuries
Having certain diseases, including arthritis and cancer

Doctors use imaging tests and other tests to diagnose Osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery.

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Check out the latest treatments for OSTEONECROSIS

➢ OSTEONECROSIS treatment research studies

➢ Oxycontin clinical trials, surveys and public health registries

Find Drug Side Effect reports

Oxycontin Side Effects

Anxiety (606)

Pain (554)

Depression (486)

Nausea (432)

Overdose (409)

Constipation (367)

Back Pain (360)

Death (321)

Arthralgia (314)

Vomiting (309)

Substance Abuse (306)

Headache (292)

Asthenia (278)

Diarrhoea (272)

Inadequate Analgesia (270)

Abdominal Pain Upper (251)

Abdominal Pain (238)

Polysubstance Abuse (233)

Coma (231)

Somnolence (227)

Confusional State (208)

Malaise (205)

Agitation (189)

Hyperhidrosis (180)

Accidental Overdose (180)

Chest Pain (174)

Product Formulation Issue (174)

Insomnia (170)

Loss Of Consciousness (167)

Amnesia (165)

Fall (159)

Dyspnoea (157)

Suicidal Ideation (152)

Anorexia (140)

Chills (140)

Dizziness (138)

Aggression (136)

Feeling Abnormal (125)

Euphoric Mood (124)

Decreased Appetite (123)

Condition Aggravated (123)

Fatigue (121)

Anger (121)

Completed Suicide (120)

Abdominal Discomfort (113)

Road Traffic Accident (113)

Blood Pressure Increased (112)

Lethargy (109)

Pruritus (102)

Myocardial Infarction (97)

➢ More

Common Meds

Abilify (10132)

Adderall (1304)

Amlodipine (6664)

Amoxicillin (4387)

Benadryl (1568)

Celebrex (12876 )

Celexa (1342)

Cialis (2975)

Cipro (8580)

Citalopram (7792)

Crestor (18839)

Cymbalta (14373)

Doxycycline (1757)

Effexor (7289)

Flexeril (435)

Flomax (2177)

Fluoxetine (4261)

Gabapentin (4593)

Hydrocodone (2469)

Ibuprofen (8222)

Lantus (10968)

Lexapro (3499)

Lipitor (17769)

Lisinopril (8919)

Lyrica (27148)

Medrol (650)

Mirena (41254)

Mobic (957)

Morphine (5356)

Naproxen (538)

Neurontin (6501)

Oxycodone (4438)

Pradaxa (13372)

Prednisone (5926)

Prilosec (2631)

Prozac (1954)

Seroquel (27216)

Simvastatin (8348)

Synthroid (4452)

Tamiflu (5585)

Topamax (3748)

Tramadol (5054)

Trazodone (1458)

Viagra (5394)

Vicodin (1153)

Wellbutrin (6324)

Xanax (2847)

Zocor (5718)

Zoloft(6792)

Zyrtec(1669)

Recent Reviews

have been taking dulotine 90mg and oxycontin 40mg pregablin 75mg would this damage my kidneys

GRAAG ZOU IK MEER WILLEN WETEN OVER OXYCONTIN BIJ ERNSTIGE COPD. HUISARTS SCHRIJFT OXYCONTIN VOOR OM DE ERGSTE BENAUWDHEID TE VERMINDEREN. IK GEBRUIK 2DD 20 MG. RETARD. LONGARTS IS TEGEN DIT GEBRUIK EN WIL ME LATEN STOPPEN. SINDS 2 JAAR

Had left half of an 40mg Oxycontin pill on my night stand! Came back about an hour later and was unable to locate pill! Time was approximately 5:00 PM! 4 to 4 1/2 hours later, younger stepsister, age 8, strangely says she took pill by accident! What

Hi, I'm not exsperiencing this first hand, but I am second hand. My bestfriend is. Let me tell you, I feel like I am. She has 7 days under he belt offically. I am so proud of her, considering how she was day 5 and 7, I don't think many people would s

How does it affect ur families

I have lost (broken off) seven lower teeth in last 60 days. Dentist say because OXYICONTIN causes severe dry mouth which creates optimal conditions for getting cavities and super fast (No cavities needing feeling at cleaning and NINE six months later

Severe back pain that goes throught to my stomach. i also feel very lehargic and i have wet myself a few times

Began the 1st of 2 three month injections of lupron in preparation for a hysterectomy in sept. 2011. Received the second injection Dec. 9, 2011 and by Dec. 16 began my suffering of ONJ osteonecrosis. I had fibroids and an enlarged uterous. I wish I h

OSTEONECROSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Rank

Status

Study

Unknown ^†

Osteonecrosis in Children With Acute Lymphoblastic Leukemia

Conditions:	Osteonecrosis; Acute Lymphoblastic Leukemia
Intervention:
Outcome Measures:	Osteonecrosis 1 year post leukemia therapy; Bone mass density and Osteonecrosis; Is Bone loss/failure to accure bone mineral and ON; Glucocorticoid dose and ON; Methotrexate dose and ON; Obesity and ON; Weight bearing and non weight bearing activities and ON; Hyperlipidemia and On; Thrombophilia and ON

Recruiting

Osteonecrosis of the Hip and Bisphosphonate Treatment

Condition:	Osteonecrosis
Interventions:	Drug: Zoledronic Acid; Drug: Placebo
Outcome Measures:	reducing pain and disability in the hip; reducing progression to femoral head collapse and the need for surgical intervention

Recruiting

Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head

Condition:	Avascular Necrosis of Femur Head
Interventions:	Biological: XCEL-MT-OSTEO-ALPHA; Procedure: Standard treatment
Outcome Measures:	Safety of XCEL-MT-OSTEO-ALPHA in Osteonecrosis of the femoral head; Feasibility of XCEL-MT-OSTEO-ALPHA in Osteonecrosis of the femoral head; Bone regeneration by measuring the necrotic angle using the modified Kerboul method; Dynamic changes of signal intensity; Clinical outcomes (pain) by Visual Analogue Scale (VAS); Clinical outcomes (SF-36); Clinical outcome (WOMAC)

Recruiting

Phase 3 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head

Condition:	Osteonecrosis of the Femoral Head
Interventions:	Drug: Core decompression/PREOB® implantation; Drug: Core decompression/placebo implantation
Outcome Measures:	WOMAC VA3.1 pain subscale; Radiological progression to fractural stages, as demonstrated by conventional X-ray with reference to the ARCO Staging; Potential occurrence of any AE or SAE, related to the product or to the procedure, using patient open non-directive questionnaire, physical examination and laboratory measurements; WOMAC VA3.1; Time to arthroplasty

Recruiting

Osteonecroses in Pediatric Patients With ALL

Conditions:	Osteonecrosis; Acute Lymphoblastic Leukaemia; Lymphoblastic Lymphoma
Intervention:
Outcome Measures:	occurence of early ON stages; ON incidence

Unknown ^†

MBCP Safety and Performance in the Osteonecrosis of Femur Head

Condition:	Osteonecrosis
Intervention:	Device: MBCP
Outcome Measures:	Infection and inflammation of the drilled area (blood and clinical assessment).; Adverse events.; Pain (Analogic Visual Scale); Hip function; Bone reconstruction evaluation through scanner and radiography

Recruiting

PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells

Condition:	Osteonecrosis of the Femoral Head
Intervention:	Procedure: bone marrow aspirate
Outcome Measure:

Recruiting

Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial

Conditions:	Osteonecrosis of the Knee; Bone Marrow Edema of the Knee
Interventions:	Drug: Ibandronate IV; Drug: Placebo
Outcome Measures:	clinical outcome (pain [VAS score]); radiological outcome (MRI knee); number of salvage therapies needed in case persistence is observed during placebo therapy

Recruiting

Osteonecrosis of the Jaw (ONJ) Case Registry

Condition:	Osteonecrosis of the Jaw (ONJ)
Intervention:
Outcome Measures:	Resolution rate and time to ONJ resolution; Explore the relationship between rate and time to ONJ resolution with ONJ severity and staging at Registry enrollment; Explore the relationship between rate and time to ONJ resolution with potential risk factors; Explore the relationship between rate and time to ONJ resolution and subsequent treatment patterns for ONJ; Explore the relationship between rate and time to ONJ resolution and treatment patterns of antiresorptive therapy

Recruiting

Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head

Condition:	Osteonecrosis
Intervention:	Procedure: core decompression
Outcome Measures:	Magnetic Resonance Imaging (MRI); Visual Analog Scale (VAS); Harris Hip Score (HHS); Western Ontario and McMaster Universities Arthritis Index (WOMAC); Radiography (RX)

Recruiting

Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee

Condition:	Spontaneous Osteonecrosis of the Knee
Intervention:	Biological: Weight reduction
Outcome Measures:	Efficacy; Safety; Reduction In AVN size by MRI

Recruiting

Treatment of Medial Compartmental Osteoarthritis Grade 1-4 (Kellgren-Lawrence) or Osteonecrosis With TomoFix™ Small or Conservatively

Conditions:	Osteoarthritis, Knee; Osteonecrosis
Intervention:
Outcome Measures:	Knee Injury and Osteoarthritis Outcome Score (KOOS); Patient-evaluated function of the knee and quality of life, a. assessed with the Oxford-12-item knee score b. assessed with the WOMAC (as calculated from the KOOS); Clinician-evaluated function of the knee, assessed with the Japanese Orthopaedic Association (JOA) score; Health-related quality of life assessed by the generic Short Form-36 (SF-36) instrument; Range of motion (ROM); Local and general pain, assessed with the Visual Analogue Scale (VAS); Possibility and duration of the Japanese sitting style; Surgery details, Postoperative treatment, Postoperative rehabilitation, Utilization; Evaluation of degenerated and regenerated cartilage (arthroscopic findings assessed according to ICRS and Outerbridge / Koshino); Radiological parameters (e.g. union, delayed union, Kellgren-Lawrence classification, joint space narrowing, tibial slope, tibia vara, patella height according to Blackburne-Peel, modified Insall-Salvati ratio, subluxation of patella); Complications and mortality

Recruiting

Bisphosphonate Biomarker Study

Conditions:	Osteoporosis, With or Without Treatment; Bisphosphonate Treatment; Atypical Femur Fracture; Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ); Healthy Volunteers
Intervention:
Outcome Measures:	Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups; Differential expression of miRNA biomarkers across participant groups within the study

Not yet recruiting

Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis

Conditions:	Aseptic;; Hip Necrosis
Interventions:	Drug: ibandronate; Drug: Placebo
Outcome Measures:	VAS pain; Imagery assessment; The Western Ontario and McMaster Universities Arthritis Index (Womac scale); Gait Analysis; Hip Harris score; Health-related quality of life EQ5D questionnaire

Recruiting

Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw

Conditions:	Solid Tumours; Bone Metastasis
Intervention:	Other: Physician Survey
Outcome Measure:	Proportion of participating oncology practitioners prescribing XGEVA® who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round)

Not yet recruiting

Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid

Conditions:	Malignant Neoplasm; Musculoskeletal Complications
Interventions:	Drug: zoledronic acid; Other: pharmacological study
Outcome Measures:	Plasma concentrations of Zol collected at visits 2, 3, 4, and 5; Urine concentrations of Zol collected at visits 2, 3, 4, and 5; Jawbone tissue concentrations of Zol collected during surgical treatment for BRONJ; Identify potential risk factors for BRONJ

Recruiting

Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee

Conditions:	Osteoarthritis, Knee; Osteonecrosis
Intervention:
Outcome Measures:	Function of the knee; Patient-evaluated function of the knee and quality of life; Clinician-evaluated function of the knee; Health-related quality of life; Range of motion (ROM); Local and general pain; Possibility and duration of the Japanese sitting style; Return to sport activities; Utilization; Evaluation of degenerated and regenerated cartilage; Radiological parameters; Complications; Anatomical alignment

Unknown ^†

A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty

Conditions:	Osteonecrosis; Femoral Neck Fracture; Implant Failure
Intervention:	Procedure: Surgical approach (ReCap Hip Resurfacing System)
Outcome Measures:	femoral head blood flow, evaluated by Laser Doppler Flowmetry; femoral head metabolism, evaluated by microdialysis; implant fixation, evaluated by RSA (radiostereogrammetric analysis); periprosthetic bone mineral density, evaluated by DEXA; gait function, evaluated by gait analysis; patient recovery, evaluated by Harris Hip Score and Visual Analogue Scale

Recruiting

Oxford Signature vs. Conventional Global Study

Conditions:	Osteoarthritis; Osteoarthritis, Knee; Osteonecrosis
Interventions:	Device: Signature Custom Guides; Procedure: Conventional Instrumentation
Outcome Measures:	Percentage of Knees Achieving Optimal Alignment; Average Number of Instrument Cases Used; Operative Time; Patient Satisfaction; Knee Function, Pain, and Range of Motion; Radiographic Outcomes; Tourniquet Time; Implant Sizing; Blood Loss; Transfusion Rate; Use of Cell-Saver; Number of Drains Used

Recruiting

ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee

Conditions:	Osteochondritis Dissecans; Osteoarthritis; Cartilage Injury; Osteonecrosis
Intervention:	Procedure: Treatment of cartilage defects in the knee
Outcome Measures:	Perceived treatment efficacy as change from baseline in KOOS score; Change from baseline in radiological signs of arthritis progression; Perceived treatment efficacy as change from baseline in Lysholm score; Time to failure